Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Introduction to Hemostasis

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Hemodialysis III: Nursing Management

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this measurement...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Plain language summary: a phase 2/3 study of plasminogen, human-tvmh for the treatment of children and adults with type 1 plasminogen deficiency.

Expert review of hematology·2026

Same author

Seventh Åland Island Meeting on von Willebrand Disease.

Haemophilia : the official journal of the World Federation of Hemophilia·2026

Same author

Von Willebrand disease.

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026

Same author

Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database.

Journal of managed care & specialty pharmacy·2026

Same author

The landmark contribution by Erik von Willebrand.

Haematologica·2026

Search research articles

Related Experiment Video

Updated: May 23, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Modern haemophilia care.

Erik Berntorp¹, Amy D Shapiro

¹Lund University, Malmö Centre for Thrombosis and Haemostasis, Skåne University Hospital, Malmö, Sweden. berntorp@med.lu.se

Lancet (London, England)

|March 30, 2012

Summary

Haemophilia care has advanced significantly, with safer clotting factor concentrates now available. Research continues to optimize prophylaxis and address inhibitor development for severe haemophilia patients.

Area of Science:

Hematology
Pharmacology
Medical History

Background:

Haemophilia care has evolved over 50 years, moving from basic treatments to sophisticated factor concentrates.
Early clotting factor concentrates (1970s) enabled home treatment but carried risks of viral transmission (HIV, hepatitis), peaking in the 1980s.
Recent decades show improved safety and availability of haemophilia therapies, including recombinant concentrates, with a shift towards preventative care and managing long-term complications.

Purpose of the Study:

To review the historical advancements in haemophilia care.
To highlight current challenges and future research directions in haemophilia treatment.
To discuss the evolving landscape of haemophilia management, focusing on prophylaxis and inhibitor development.

Main Methods:

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 23, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Historical review of haemophilia treatment evolution.
Analysis of advancements in clotting factor concentrate development, including recombinant products.
Discussion of current clinical practices and ongoing research in haemophilia management.

Main Results:

Significant improvements in haemophilia care safety and efficacy over the past 40-50 years.
Recombinant concentrates have enhanced therapy safety and availability.
Key research questions remain regarding the optimal initiation, duration, and cessation of prophylaxis, and managing treatment inhibitors.

Conclusions:

Modern haemophilia care emphasizes prophylaxis and sequelae management, driven by safer and more available therapies.
Development of inhibitors remains a major clinical challenge, necessitating ongoing research.
Future therapeutic advancements focus on novel products with improved pharmacokinetic profiles to further enhance patient outcomes.